Stock Events

Stock Events

Vicore Pharma AB 

€0.9490
6
+€0.04+4.4% Today

Statistics

Day High
0.949
Day Low
0.913
52W High
1.19
52W Low
0.644
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

21AugExpected
Q1 2026
Next
-0.04
-0.04
-0.04
-0.03
Expected EPS
-0.041004765
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6Y4.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap113.41B
Vertex Pharmaceuticals is involved in developing therapies for treating cystic fibrosis and other serious diseases, overlapping with Vicore's focus on rare lung disorders.
Incyte
INCY
Mkt Cap20.45B
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, including treatments for pulmonary diseases.
Lakefront Biotherapeutics NV
GLPG
Mkt Cap1.86B
Galapagos NV specializes in drug discovery and development for inflammation and other diseases, competing in the same therapeutic areas as Vicore.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.97B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic disorders that overlap with Vicore's market.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.62B
Regeneron Pharmaceuticals is known for its development of treatments for serious medical conditions, including respiratory and inflammatory diseases, competing with Vicore's product pipeline.
Gilead Sciences
GILD
Mkt Cap160.36B
Gilead Sciences' involvement in pulmonary and fibrotic diseases places it in direct competition with Vicore's therapeutic areas.
Novo Nordisk
NVO
Mkt Cap190.31B
Novo Nordisk is engaged in the discovery and development of biological therapies, including areas that could compete with Vicore's interest in rare diseases.

About

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Show more...
CEO
ISIN
SE0007577895

Listings

STU
DE
6Y4.STU
ST
SE
VICO.ST
F
DE
6Y4.F

0 Comments

Share your thoughts

FAQ

What is Vicore Pharma AB stock price today?▼
The current price of 6Y4.STU is €0.95 EUR — it has increased by +4.4% in the past 24 hours. Watch Vicore Pharma AB stock price performance more closely on the chart.
What is Vicore Pharma AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vicore Pharma AB stocks are traded under the ticker 6Y4.STU.
Is Vicore Pharma AB stock price growing?▼
6Y4.STU stock has fallen by -1.56% compared to the previous week, the month change is a -10.13% fall, over the last year Vicore Pharma AB has showed a +15.73% increase.
When is the next Vicore Pharma AB earnings date?▼
Vicore Pharma AB is going to release the next earnings report on August 21, 2026.
What were Vicore Pharma AB earnings last quarter?▼
6Y4.STU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was -0.04 EUR resulting in a +18.75% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Vicore Pharma AB located?▼
Vicore Pharma AB operates in the Other sector.
When did Vicore Pharma AB complete a stock split?▼
Vicore Pharma AB has not had any recent stock splits.